Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Y Liu, SK Barta - American journal of hematology, 2019 - Wiley Online Library
Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
Diffuse large B-cell lymphoma
S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
AE Tron, MA Belmonte, A Adam, BM Aquila… - Nature …, 2018 - nature.com
Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing
induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and …
induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and …
Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance …
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study,
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
LH Sehn, RD Gascoyne - Blood, The Journal of the American …, 2015 - ashpublications.org
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is a biologically heterogeneous and clinically
aggressive disease. Here, we explore the role of bromodomain and extra-terminal domain …
aggressive disease. Here, we explore the role of bromodomain and extra-terminal domain …
Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies
DW Scott, A Mottok, D Ennishi, GW Wright… - Journal of clinical …, 2015 - ascopubs.org
Purpose To evaluate the prognostic impact of cell-of-origin (COO) subgroups, assigned
using the recently described gene expression–based Lymph2Cx assay in comparison with …
using the recently described gene expression–based Lymph2Cx assay in comparison with …
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL
A Schmitt, W Xu, P Bucher, M Grimm… - Blood, The Journal …, 2021 - ashpublications.org
Despite the development of novel targeted drugs, the molecular heterogeneity of diffuse
large B-cell lymphoma (DLBCL) still poses a substantial therapeutic challenge. DLBCL can …
large B-cell lymphoma (DLBCL) still poses a substantial therapeutic challenge. DLBCL can …
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
AM Petrich, M Gandhi, B Jovanovic… - Blood, The Journal …, 2014 - ashpublications.org
Patients with double-hit lymphoma (DHL), which is characterized by rearrangements of MYC
and either BCL2 or BCL6, face poor prognoses. We conducted a retrospective multicenter …
and either BCL2 or BCL6, face poor prognoses. We conducted a retrospective multicenter …
Genetics of follicular lymphoma transformation
L Pasqualucci, H Khiabanian, M Fangazio… - Cell reports, 2014 - cell.com
Follicular lymphoma (FL) is an indolent disease, but 30%–40% of cases undergo histologic
transformation to an aggressive malignancy, typically represented by diffuse large B cell …
transformation to an aggressive malignancy, typically represented by diffuse large B cell …